PD-L1 biomarker testing sales will expand through 2036, with PD-L1 biomarker testing at 50.4% within the product type segment in 2026. The market was valued at USD 777.20 million in 2025, is projected to reach USD 1830.69 million by 2036 and is forecast to record an 8.1% CAGR between 2026 and 2036.